Biosimilar Use Should Be Required Under Publicly Funded Systems: JSGM Pres.

JSGM President Masaki Muto Masaki Muto, president of the Japan Society of Generic Medicines (JSGM), insisted that patients who use systems that are largely funded by the public should be required to use biosimilars rather than original biologics whenever possible...read more